Accuracy and selection success in yield trial analyses

Summary Yield trials serve research purposes of estimation and selection. Order statistics are used here to quantify the successes or problems to be expected in selection tasks commonly encountered in breeding and agronomy. Greater accuracy of yield estimates implies greater selection success. A New York soybean yield trial serves as a specific example. The Additive Main effects and Multiplicative Interaction (AMMI) statistical model is used to increase the accuracy of these soybean yield estimates, thereby increasing the probability of successfully selecting, on the basis of the empirical yield data, that genotype which has the maximum true mean. The statistical strategy for increasing accuracy is extremely cost effective relative to the alternative strategy of increasing the number of replications. Better selections increase the speed and effectiveness of breeding programs, and increase the reliability of variety recommendations. Selection tasks are frequently more difficult than may be suspected.This research was supported by the Rhizobotany Project of the USDA-ARS     

Supplementation with vitamin E but not with vitamin C lowers lipid peroxidation in vivo in mildly hypercholesterolemic men

Although the use of vitamin E supplements has been associated with a reduction in coronary events, assumed to be due to lowered lipid peroxidation, there are no previous long-term clinical trials into the effects of vitamin C or E supplementation on lipid peroxidation in vivo. Here, we have studied the long-term effects of vitamins C and E on plasma F₂-isoprostanes, a widely used marker of lipid peroxidation in vivo. As a study cohort, a subset of the “Antioxidant Supplementation in Atherosclerosis Prevention” (ASAP) study was used. ASAP is a double-masked placebo-controlled randomized clinical trial to study the long-term effect of vitamin C (500 mg of slow release ascorbate daily), vitamin E (200 mg of d-α-tocopheryl acetate daily), both vitamins (CellaVie^®), or placebo on lipid peroxidation, atherosclerotic progression, blood pressure and myocardial infarction (n = 520 at baseline). Lipid peroxidation measurements were carried out in 100 consecutive men at entry and repeated at 12 months. The plasma F₂-isoprostane concentration was lowered by 17.3% (95% CI 3.9–30.8%) in the vitamin E group (p = 0.006 for the change, as compared with the placebo group). On the contrary, vitamin C had no significant effect on plasma F₂-isoprostanes as compared with the placebo group. There was also no interaction in the effect between these vitamins. In conclusion, long-term oral supplementation of clinically healthy, but hypercholesterolemic men, who have normal vitamin C and E levels with a reasonable dose of vitamin E lowers lipid peroxidation in vivo, but a relatively high dose of vitamin C does not. This observation may provide a mechanism for the observed ability of vitamin E supplements to prevent atherosclerosis.     

Enhanced fructose levels in field grown potato tubers expressing a thermostable glucose isomerase

A thermostable glucose isomerase was expressed in Solanum tuberosum Desirée using the tuber-specific granular-bound starch synthase promoter. The fructose content was substantially increased in microtubers, greenhouse grown tubers as well as tubers produced in field trials as compared with the controls. Furthermore, the tuber yield of field grown potatoes was enhanced by 30% in the transgenic lines (from 1.04 kg/plant in the wild type to 1.36 kg/plant in the transgenic lines).     

人心脏型脂肪酸结合蛋白检测试剂盒的临床评价

目的评价人心脏型脂肪酸结合蛋白(H-FABP)检测试剂盒(胶体金法)在急性心肌梗死(AMI)诊断中的价值。方法采用平行、盲法、对照的对比试验设计,比较其试验产品和对比产品对诊断AMI的敏感性、特异性、准确性。结果共测定240份临床血液标本。试验产品和对比产品的阳性符合率为100%,阴性符合率为96.15%,总符合率为97.92%。对比产品和试验产品结果不一致的5例标本以临床诊断结果为标准进行验证后,试验产品与临床诊断结果的阳性符合率为100%,总符合率为100%。采用Kappa检验考核两种产品测定结果的一致性,Kappa指数为0.958。经McNamara's test分析,两产品之间无差异,χ2=3.20,P>0.05。结论试验产品显示出较好的诊断价值,可以作为AMI早期诊断标志物,试验产品与对比产品等效。     

Transnational Medicine in Public Arenas: Aids Treatments in the South

This article looks at the AIDS-related controversy surrounding the experiments on and the availability of medicines in southern countries. It situates these debates in a longer-term history of transnational medicine. It highlights the rise of international therapeutic modernity at the beginning of the 1990s, based on the strict regulation of clinical trials and on the formalization of the international ethical rules governing experiments. This rise helped to change radically the reception of experiments conducted in southern countries around AIDS. With regard to this new ethics applied to clinical trials in southern countries, this article goes on to demonstrate the confrontation at the end of the 1990s between two different approaches to the universalization of healthcare. Finally, it shows how new laws on international trade have reinitiated this confrontation. Through this story, the article suggests in what sense the study of the political transformations of transnational medicine could offer a new field of investigation for the social sciences.     

Are Phase 1 Trials Therapeutic? Risk,Ethics, and Division of Labor

Despite their crucial role in the translation of pre‐clinical research into new clinical applications, phase 1 trials involving patients continue to prompt ethical debate. At the heart of the controversy is the question of whether risks of administering experimental drugs are therapeutically justified. We suggest that prior attempts to address this question have been muddled, in part because it cannot be answered adequately without first attending to the way labor is divided in managing risk in clinical trials. In what follows, we approach the question of therapeutic justification for phase 1 trials from the viewpoint of five different stakeholders: the drug regulatory authority, the IRB, the clinical investigator, the referring physician, and the patient. Our analysis shows that the question of therapeutic justification actually raises multiple questions corresponding to the roles and responsibilities of the different stakeholders involved. By attending to these contextual differences, we provide more coherent guidance for the ethical negotiation of risk in phase 1 trials involving patients. We close by discussing the implications of our argument for various perennial controversies in phase 1 trial practice.